BIOLINERX Ltd/S (BLRX) Issues Quarterly Earnings Results, Meets Expectations

BIOLINERX Ltd/S (NASDAQ:BLRX) announced its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06), reports.

Shares of BLRX stock traded down $0.01 on Friday, hitting $0.70. 391,694 shares of the stock traded hands, compared to its average volume of 1,728,884. The stock has a market cap of $78.77 million, a price-to-earnings ratio of -2.59 and a beta of 0.87. BIOLINERX Ltd/S has a twelve month low of $0.67 and a twelve month high of $1.84.

A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new stake in shares of BIOLINERX Ltd/S (NASDAQ:BLRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned about 1.27% of BIOLINERX Ltd/S at the end of the most recent quarter. Hedge funds and other institutional investors own 34.69% of the company’s stock.

Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a research note on Tuesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of BIOLINERX Ltd/S in a research note on Monday, July 30th. MED assumed coverage on shares of BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They set a “market perform” rating on the stock. Finally, Oppenheimer set a $3.00 target price on shares of BIOLINERX Ltd/S and gave the stock a “buy” rating in a research note on Friday. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. BIOLINERX Ltd/S currently has an average rating of “Buy” and a consensus price target of $2.50.

TRADEMARK VIOLATION WARNING: This report was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at


BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Earnings History for BIOLINERX Ltd/S (NASDAQ:BLRX)

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with's FREE daily email newsletter.

Leave a Reply